X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (948) 948
Publication (53) 53
Book Chapter (3) 3
Book Review (3) 3
Dissertation (3) 3
Conference Proceeding (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
edaravone (901) 901
antipyrine - analogs & derivatives (420) 420
index medicus (351) 351
animals (343) 343
male (289) 289
rats (240) 240
antipyrine - pharmacology (217) 217
oxidative stress (212) 212
free-radical scavenger (201) 201
humans (192) 192
free radical scavengers - pharmacology (161) 161
neurosciences (156) 156
antipyrine - therapeutic use (149) 149
pharmacology & pharmacy (148) 148
mci-186 (140) 140
free radical scavengers - therapeutic use (123) 123
apoptosis (116) 116
ischemia (116) 116
female (108) 108
brain (105) 105
mice (103) 103
stroke (102) 102
rats, sprague-dawley (100) 100
injury (90) 90
antioxidants (84) 84
disease models, animal (83) 83
oxidative stress - drug effects (83) 83
clinical neurology (82) 82
neuroprotection (78) 78
damage (70) 70
reactive oxygen species (70) 70
antipyrine - administration & dosage (65) 65
free radical scavenger (64) 64
free radicals (62) 62
amyotrophic lateral sclerosis (61) 61
cerebral-ischemia (60) 60
rats, wistar (60) 60
aged (59) 59
biochemistry & molecular biology (59) 59
apoptosis - drug effects (58) 58
expression (57) 57
neuroprotective agents - pharmacology (57) 57
dose-response relationship, drug (55) 55
antioxidant (54) 54
cell biology (54) 54
time factors (54) 54
analysis (53) 53
middle aged (53) 53
neurology (52) 52
reactive oxygen species - metabolism (51) 51
surgery (51) 51
inflammation (49) 49
medicine, research & experimental (49) 49
rat (49) 49
cells, cultured (48) 48
neurons (48) 48
treatment outcome (48) 48
original (45) 45
free radical scavengers - administration & dosage (44) 44
nitric-oxide (43) 43
activation (42) 42
cells (42) 42
free radical (42) 42
adult (41) 41
brain edema (40) 40
disease (40) 40
neuroprotective agents - therapeutic use (39) 39
immunohistochemistry (38) 38
rodents (38) 38
antipyrine - chemistry (37) 37
care and treatment (37) 37
reperfusion injury (37) 37
research (37) 37
cerebral infarction (36) 36
original article (36) 36
brain ischemia - drug therapy (35) 35
chemistry, multidisciplinary (35) 35
health aspects (35) 35
lipid-peroxidation (35) 35
reperfusion (35) 35
nitric oxide (34) 34
radical scavenger (34) 34
als (33) 33
infarction (33) 33
ischemia-reperfusion injury (33) 33
model (33) 33
stroke - drug therapy (32) 32
antioxidants - pharmacology (31) 31
antipyrine - metabolism (31) 31
brain - drug effects (31) 31
cerebral ischemia (31) 31
research article (31) 31
inhibition (30) 30
lipid peroxidation - drug effects (30) 30
superoxide (30) 30
neurons - drug effects (28) 28
peripheral vascular disease (28) 28
proteins (28) 28
reperfusion injury - prevention & control (28) 28
spinal cord injury (28) 28
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (899) 899
Japanese (83) 83
Chinese (10) 10
Turkish (5) 5
Czech (1) 1
Korean (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neuroscience Letters, ISSN 0304-3940, 10/2019, Volume 711, p. 134438
Restoration of cellular microenvironment is important in the treatment of neurodegenerative diseases for optimal functioning and survival of neurons. Oxidative... 
3-Nitrotyrosine | Edaravone | Malondialdehyde | Parkinson’s disease | Caffeine | Rotenone
Journal Article
Journal of Clinical Biochemistry and Nutrition, ISSN 0912-0009, 11/2017, Volume 61, Issue 3, pp. 159 - 163
Journal Article
Journal of Clinical Biochemistry and Nutrition, ISSN 0912-0009, 2017
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) has been used as a free radical scavenging drug for the treatment of acute ischemic stroke in Japan since 2001.... 
hydrogen peroxide | edaravone trimer | edaravone | sodium bisulfite | bisulfite adduct
Journal Article
Brain Research, ISSN 0006-8993, 11/2019, Volume 1723, p. 146379
Abnormal accumulation of amyloid-β (Aβ) peptide defines progression of Alzheimer’s disease (AD) pathology in brain. Here, we investigated expressive changes of... 
Chronic cerebral hypoperfusion | Edaravone | Alzheimer’s disease | Amyloid-β transport
Journal Article
Journal Article
BRAIN RESEARCH, ISSN 0006-8993, 11/2019, Volume 1723, p. 146379
Abnormal accumulation of amyloid-beta (A beta) peptide defines progression of Alzheimer's disease (AD) pathology in brain. Here, we investigated expressive... 
EDARAVONE MCI-186 | OXIDATIVE STRESS | Amyloid-beta transport | FREE-RADICAL SCAVENGER | NEURODEGENERATION | NEUROSCIENCES | PEPTIDE | BRAIN-BARRIER | A-BETA | DOUBLE-BLIND | Chronic cerebral hypoperfusion | Edaravone | ACCUMULATION | DYSFUNCTION | Alzheimer's disease
Journal Article
Molecular medicine (Cambridge, Mass.), ISSN 1076-1551, 12/2019, Volume 25, Issue 1, pp. 54 - 10
Intestinal mucosa barrier dysfunction after burn injury is an important factor for causing mortality of burn patients. The current study established a burn... 
Oxidative stress | Intestinal mucosa damage | Edaravone | Apoptosis | MiR-320
Journal Article
Drug Design, Development and Therapy, ISSN 1177-8881, 07/2018, Volume 12, pp. 2051 - 2069
Background: Edaravone (EDR) is known for its free radical scavenging, antiapoptotic, antineerotic, and anticytokine effects in neurological and... 
Oral bioavailability | Soluplus | Edaravone | Permeability | Metabolism | Nanotechnology | CHEMISTRY, MEDICINAL | Soluplus (R) a | ALZHEIMERS-DISEASE | VIVO EVALUATION | permeability | FREE-RADICAL SCAVENGER | edaravone | SOLUBLE DRUGS | AMYOTROPHIC-LATERAL-SCLEROSIS | POLYMERIC MICELLES | AQUEOUS-SOLUTION | DELIVERY-SYSTEM | nanotechnology | PHARMACOLOGY & PHARMACY | metabolism | oral bioavailability | NRF2/HO-1 PATHWAY | DRUG DELIVERY | Administration, Oral | Free Radical Scavengers - chemistry | Humans | Solubility | Free Radical Scavengers - administration & dosage | Biological Availability | Edaravone - administration & dosage | Drug Carriers - chemistry | Dose-Response Relationship, Drug | Edaravone - pharmacokinetics | Drug Compounding | Free Radical Scavengers - pharmacokinetics | Polymers - chemistry | Kinetics | Edaravone - chemistry | Usage | Nervous system diseases | Care and treatment | Hydrogen | Therapeutics | Clopidogrel | Amyotrophic lateral sclerosis | Homeopathy | Materia medica and therapeutics | Oxidative stress | Intravenous administration | Pathogenesis | Amorphization | Materials selection | Hydrogen bonding | Optimization | Dental materials | Chemical properties | Bonding | Cerebral infarction | Hydrogen storage | Free radicals | Medical treatment | Pharmacology | Bioavailability | Evaporation | Dissolution | Dispersion | Carriers | Neurological diseases | Organic chemistry | Nef protein | Miscibility | Infarction | Physicochemical properties | Drugs | Drug delivery systems | Clinical trials | Molecular weight | Polyethylene glycol | Scavenging | FDA approval | Alzheimers disease
Journal Article
Journal Article
Journal of Clinical Biochemistry and Nutrition, ISSN 0912-0009, 2017, Volume 61, Issue 3, pp. 159 - 163
Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) has been used as a free radical scavenging drug for the treatment of acute ischemic stroke in Japan since 2001.... 
edaravone trimer | edaravone | sodium bisulfite | bisulfite adduct | hydrogen peroxide | NUTRITION & DIETETICS | Original
Journal Article
International Immunopharmacology, ISSN 1567-5769, 12/2019, Volume 77, p. 105967
The drug edaravone (EDA) is prescribed for the treatment of patients with amyotrophic lateral sclerosis or after an acute cerebral infarction. This synthetic... 
Oxygen radicals | Chemotherapy | Immunotherapy | ALS | Inflammation | Edaravone | Radiotherapy | Cancer | CELLS | OXIDATIVE STRESS | INDUCED APOPTOSIS | CISPLATIN-INDUCED NEPHROTOXICITY | SCAVENGER EDARAVONE | PHARMACODYNAMICS | IMMUNOLOGY | DAMAGE | PROTECTS | PHARMACOLOGY & PHARMACY | DYSFUNCTION | OMAVELOXOLONE
Journal Article
Journal of Molecular Neuroscience, ISSN 0895-8696, 11/2018, Volume 66, Issue 3, pp. 322 - 341
Journal Article